We are live on ! Find out more
CYTK icon

Cytokinetics

192 hedge funds and large institutions have $1.74B invested in Cytokinetics in 2021 Q1 according to their latest regulatory filings, with 32 funds opening new positions, 62 increasing their positions, 63 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

88% more first-time investments, than exits

New positions opened: 32 | Existing positions closed: 17

65% more call options, than puts

Call options by funds: $5.35M | Put options by funds: $3.23M

15% more capital invested

Capital invested by funds: $1.51B → $1.74B (+$224M)

8% more funds holding

Funds holding: 178192 (+14)

2.22% more ownership

Funds ownership: 103.03%105.26% (+2.2%)

0% more funds holding in top 10

Funds holding in top 10: 55 (0)

2% less repeat investments, than reductions

Existing positions increased: 62 | Existing positions reduced: 63

Holders
192
Holders Change
+14
Holders Change %
+7.87%
% of All Funds
3.37%
Holding in Top 10
5
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.09%
New
32
Increased
62
Reduced
63
Closed
17
Calls
$5.35M
Puts
$3.23M
Net Calls
+$2.11M
Net Calls Change
-$5.53M
Name Holding Trade Value Shares
Change
Change in
Stake
IHAM
26
Integral Health Asset Management
New York
$16.3M +$3.74M +175,000 +33%
LGM
27
Logos Global Management
California
$16.3M +$14.9M +700,000 New
Bank of New York Mellon
28
Bank of New York Mellon
New York
$16M -$3.2K -150 -0%
CCM
29
CAAS Capital Management
New York
$15.6M +$14.3M +671,382 New
OM
30
Opaleye Management
Massachusetts
$13.5M -$59.8K -2,800 -0.5%
Two Sigma Investments
31
Two Sigma Investments
New York
$12.7M +$9.07M +424,969 +351%
Principal Financial Group
32
Principal Financial Group
Iowa
$12M +$15K +704 +0.1%
Charles Schwab
33
Charles Schwab
California
$11M +$327K +15,337 +3%
HM
34
HealthCor Management
New York
$10.8M +$9.88M +462,500 New
PCM
35
Peregrine Capital Management
Minnesota
$10.4M -$2.33M -109,130 -20%
Invesco
36
Invesco
Georgia
$9.78M -$481K -22,516 -5%
PAMU
37
Pictet Asset Management (UK)
United Kingdom
$9.77M
SI
38
Sofinnova Investments
California
$9.06M -$2.53M -118,674 -23%
Point72 Asset Management
39
Point72 Asset Management
Connecticut
$8.71M -$16.9M -791,694 -68%
AllianceBernstein
40
AllianceBernstein
Tennessee
$8.43M +$5.57M +260,794 +257%
CM
41
CM Management
Florida
$7.56M
PA
42
Pinnacle Associates
New York
$7.54M -$756K -35,425 -10%
CS
43
Candriam SCA
Luxembourg
$7.5M
Citadel Advisors
44
Citadel Advisors
Florida
$7.48M +$4.73M +221,545 +221%
Ameriprise
45
Ameriprise
Minnesota
$7.35M +$317K +14,853 +5%
N
46
Nuveen
North Carolina
$6.88M -$1.57M -73,338 -20%
SDIC
47
South Dakota Investment Council
South Dakota
$6.47M -$450K -21,081 -7%
Marshall Wace
48
Marshall Wace
United Kingdom
$6.37M +$4.73M +221,628 +424%
BCM
49
Burrage Capital Management
Massachusetts
$5.69M -$29.1K -1,363 -0.6%
Assenagon Asset Management
50
Assenagon Asset Management
Luxembourg
$5.37M +$4.93M +231,032 New

CYTK Hedge Fund Activity: Q1 2021 in Review

192 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Cytokinetics (CYTK) for Q1 2021, worth a combined $1.74B — up 15% from $1.51B a quarter earlier.

Buyers outnumbered sellers: 32 funds opened new CYTK positions and 17 closed out — a net gain of 15 holders — while 62 added to existing stakes and 63 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $59.9M. The largest seller was BVF Inc, exiting entirely with an estimated $101M sold.

  • 192 institutional investors held Cytokinetics (CYTK) as of Q1 2021, up from 178 in Q4 2020.
  • Funds reported $1.74B of Cytokinetics stock for Q1 2021, up 15% quarter-over-quarter.
  • 32 funds opened new Cytokinetics positions in Q1 2021 and 17 closed out, a net change of +15 holders.
  • The largest Cytokinetics buyer in Q1 2021 was Fidelity Investments, an estimated $59.9M added.
  • The largest Cytokinetics seller in Q1 2021 was BVF Inc, an estimated $101M sold.

Based on aggregated 13F filings for Q1 2021.